RT @shilpaonc
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
#bonumce #renalcell #NephTwitter #medtwitter #clear #keynote426 #checkmate9er #checkmate214 #TumorBoardTuesday
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter
Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214
#TumorBoardTuesday #bonumce #renalcell #NephTwitter #medtwitter #clear #keynote426 #checkmate9er #checkmate214
RT @TumorBoardTues
12/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal Phase 3 trials of TKI-ICI combos🔬
#KEYNOTE426 #CLEAR #CHECKMATE9ER #JAVELINrenal101
🔹Diarrhea
🔸HTN
🔹Hypothyroidism
🔸Fatigue
🔹PPES
🔸Loss of appetite
#bonumce #renalcell #OncTwitter #NephTwitter #medtwitter #keynote426 #clear #checkmate9er #javelinrenal101
RT @TumorBoardTues
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
#renalcell #keynote426 #clear #checkmate9er #checkmate214
12/#TumorBoardTuesday #BonumCE #RenalCell
#OncTwitter #NephTwitter #MedTwitter
🔬Common tox in pivotal Phase 3 trials of TKI-ICI combos🔬
#KEYNOTE426 #CLEAR #CHECKMATE9ER #JAVELINrenal101
🔹Diarrhea
🔸HTN
🔹Hypothyroidism
🔸Fatigue
🔹PPES
🔸Loss of appetite
#bonumce #renalcell #OncTwitter #NephTwitter #medtwitter #keynote426 #clear #checkmate9er #javelinrenal101
5/#TumorBoardTuesday #RenalCell
🔑Ph3 trls #KEYNOTE426, #CLEAR, #CheckMate9ER, #CheckMate214
💎Each combo regimen ⬆️PFS, OS, & ORR vs sunitinib
💎Axi-avelumab approved but OS data immature
💎Benefit across IMDC risk groups
💎Axi-pembro=longest f/u among approved TKI-ICI in RCC
#renalcell #keynote426 #clear #checkmate9er #checkmate214